Autologous bone marrow transplantation (ABMT) in human acute leukemia is limited by the presence of occult viable tumor cells in the marrow graft. The proposed preclinical research will develop strategies to eliminate potentially drug-resistant leukemic cells from marrow suspensions before ABMT by ex vivo incubation with antineoplastic agents (""""""""chemopurging""""""""), using the model of human acute myeloid leukemia (AML) in the Lewis x Brown Norway hybrid (LPN) rat. Suspensions of LBN AML and/or normal marrow cells will be incubated with graded concentrations of selected chemotherapeutic agents (4-hydroperoxy-cyclophosphamide [4HC], bleomycin, etoposide, m-AMSA, or vincristine). The dose-dependent effects of incubation with each drug on the growth of leukemic and normal hematopoietic cells will be compared with complementary in vitro clonogenic assays for leukemic (CFU-Leuk) and normal hematopoietic progenitors (CFU-GM), and in vivo assessment of engraftment, prolongation of median survival time (MST), and/or leukemia- free survival (LFS) after transplantation of chemopurged normal LBN marrow, AML cells, or mixtures thereof (to approximate residual leukemia in remission bone marrow) into syngeneic recipients. Agents that demonstrate synergistic antitumor effects without additive stem cell toxicity will thus be identified and further evaluated in sequential drug-incubation studies. To determine the efficacy of these chemopurging regimens in a model of relapsed drug-resistant human AML, a cyclophosphamide (CY)-resistant subline of LBN AML will be developed by chronic exposure to CY in vivo and to 4HC in vitro. Potential mechanisms of CY resistance such as elevated aldehyde dehydrogenase (ALDH) activity, and strategies to reverse resistance by ex vivo incubation with ALDH inhibitors, an approach that is relevant to chemopurging of autografts in human AML, will be evaluated in this subline. Finally, methods that may enhance differential sensitivity of leukemic vs. normal marrow stem cells in ex vivo chemopurging regimens will be studied. The effects of incubation with bryostatin (BRYO), a novel antitumor agent that activates protein kinase C and stimulates normal human hematopoiesis, on the growth of leukemic and normal rat marrow cells will be examined by in vitro clonogenic assays, by observation of engraftment, increases in MST, and/or LFS after transplantation of BRYO-treated normal marrow and/or AML cells into LBN rats, and by in vivo administration of BRYO to leukemic animals. The ability of coincubation with BRYO to potentiate the antileukemic effects and minimize the stem-cell toxicity of chemotherapeutic agents will also be determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA040282-06
Application #
3180049
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1987-01-01
Project End
1993-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Adamkiewicz, T V; Mehta, P S; Boyer, M W et al. (2004) Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant 34:405-11
Mogul, M J; Forte, K J; Holland, H K et al. (1997) Steroid-refractory cutaneous graft-versus-host disease after transplantation of haploidentical parental CD34+ cells in children with Down's syndrome and recurrent acute leukemia. J Pediatr Hematol Oncol 19:142-4
Turner, C W; Yeager, A M; Waller, E K et al. (1996) Engraftment potential of different sources of human hematopoietic progenitor cells in BNX Mice. Blood 87:3237-44
Zhou, M; Gu, L; James, C D et al. (1995) Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia. Leukemia 9:1159-61
Quigley, P M; Yeager, A M; Loughlin, G M (1994) The effects of bone marrow transplantation on pulmonary function in children. Pediatr Pulmonol 18:361-7
Yeager, A M (1993) Recent developments in experimental bone marrow transplantation. Curr Opin Oncol 5:282-9
Yeager, A M; Vogelsang, G B; Jones, R J et al. (1993) Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 11:215-20
Graham, M L; Yeager, A M; Leventhal, B G et al. (1992) Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. J Clin Oncol 10:1857-64
Yeager, A M; Shinn, C; Farmer, E R et al. (1992) Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cell transplantation in mice. Bone Marrow Transplant 9:199-204
Yeager, A M; Vogelsang, G B; Jones, R J et al. (1992) Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031-5

Showing the most recent 10 out of 26 publications